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ABSTRACT
The transcriptional repressor B lymphocyte-induced
maturation protein-1 (BLIMP1) regulates gene ex-
pression and cell fate. The DNA motif bound by
BLIMP1 in vitro overlaps with that of interferon regu-
latory factors (IRFs), which respond to inflamma-
tory/immune signals. At such sites, BLIMP1 and
IRFs can antagonistically regulate promoter
activity. In vitro motif selection predicts that only a
subset of BLIMP1 or IRF sites is subject to antag-
onistic regulation, but the extent to which antagon-
ism occurs is unknown, since an unbiased
assessment of BLIMP1 occupancy in vivo is
lacking. To address this, we identified an extended
set of promoters occupied by BLIMP1. Motif discov-
ery and enrichment analysis demonstrate that
multiple motif variants are required to capture
BLIMP1 binding specificity. These are differentially
associated with CpG content, leading to the obser-
vation that BLIMP1 DNA-binding is methylation sen-
sitive. In occupied promoters, only a subset of
BLIMP1 motifs overlap with IRF motifs. Conversely,
a distinct subset of IRF motifs is not enriched
amongst occupied promoters. Genes linked to
occupied promoters containing overlapping
BLIMP1/IRF motifs (e.g. AIM2, SP110, BTN3A3) are
shown to constitute a dynamic target set which is
preferentially activated by BLIMP1 knock-down.
These data confirm and extend the competitive
model of BLIMP1 and IRF interaction.
INTRODUCTION
The transcriptional repressor PR domain containing 1
(PRDM1), better known as B-lymphocyte-induced
maturation protein-1 (BLIMP1), is essential for normal
development and immunity (1). In the immune system,
the central role of BLIMP1 during terminal B-cell diﬀer-
entiation is indicated by the failure of plasma cell diﬀer-
entiation in murine Blimp1 knockout B-cells and the
repression of key gene expression programmes following
ectopic BLIMP1 expression in human cell lines (2–4). In
the absence of Blimp1 in T-cells, mice develop an inﬂam-
matory bowel disease, which reﬂects a role for BLIMP1 in
the control of eﬀector T-cell populations (5,6). This has
been underscored by recent data establishing the role for
BLIMP1 in the control of speciﬁc CD4 and CD8 T-cell
populations (7–11).
BLIMP1 represses transcription by binding to speciﬁc
target sites in DNA and recruiting co-regulatory mol-
ecules (12–16). BLIMP1 contains ﬁve carboxy-terminal
C2H2 Zn-ﬁnger domains, the ﬁrst four of these are
highly evolutionarily conserved, and of these, the ﬁrst
two are necessary to confer DNA binding speciﬁcity
(12,17). To date, only a limited number of regulatory
elements have been characterized as direct targets of
BLIMP1 and the majority of these have been identiﬁed
in promoters (18). During plasma cell diﬀerentiation,
BLIMP1 acts via promoter elements to repress core tran-
scription factors such as PAX5,MYC and CIITA (19–21).
However, BLIMP1 can also act via distant regulatory
elements, and several important regulatory associations
of this type have been recently identiﬁed in T cells (22,23).
The function of BLIMP1, interferons (IFNs) and the
interferon regulatory factor (IRF) family of transcription
factors are closely interlinked, as originally indicated by
the isolation of BLIMP1 as a post-induction repressor of
the IFN- promoter (24). The optimal DNA sequences
bound by human and murine BLIMP1 in vitro are essen-
tially identical, and similar to that bound by the IRF
family, in particular IRF1 and IRF2 (25–27). The nature
of the consensus sequence recognized by BLIMP1 in vitro
predicts the existence of at least two distinct sets of
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BLIMP1 target sites. These either show minimal overlap
with IRF binding sites (e.g. PAX5) or overlap with
extended IRF elements (IRF-E; e.g. PSMB8, PSMB10).
This distinction is functionally signiﬁcant since at pro-
moters containing BLIMP1 sites which overlap with
IRF-Es, binding of BLIMP1 and IRFs is mutually exclu-
sive and promoter activity is regulated by the antagonistic
action of these transcription factors (28,29). Conversely,
not all IRF sites are predicted to be recognized by
BLIMP1 (24,26). Two point mutations are suﬃcient to
eliminate BLIMP1 binding to IRF-Es, while preserving
IRF binding and IFN responsive regulation (28,29).
IRFs play critical roles in mediating responses to cyto-
kines and innate immune stimuli, and may themselves
act as positive and negative regulators of promoter
activity (30). The similarity in motifs selected in vitro
suggests that the overlap in sequence recognition by
IRFs and BLIMP1 imposes an additional level of
control in cells in which these factors are co-expressed.
However, in the absence of an unbiased analysis of
in vivo occupancy, the generality of these predictions is
uncertain.
To address this question, we have deﬁned an extended
set of promoters directly bound by BLIMP1 in human
cells. We use this target set to establish the optimal
DNA sequence motifs bound by BLIMP1 in vivo,
capturing subtle complexity of binding speciﬁcity, and a
link between motif type and promoter CpG content. We
demonstrate that only a subset of occupied promoters is
associated with overlapping BLIMP1 and IRF motifs, and
conversely that a subset of IRF motifs is not associated
with BLIMP1 occupancy. In a model system in which
BLIMP1 is co-expressed with IRFs we ﬁnd that genes
linked to overlapping motifs, despite having amongst the
highest predicted BLIMP1 binding aﬃnities, are the most
labile target genes upon BLIMP1 knock-down. This
unbiased experimental approach thus conﬁrms two key
predictions of the antagonistic regulation model,
providing further evidence for the functional linkage
between BLIMP1 and IRFs.
METHODS
Cell lines, antibodies and siRNA
U266 and Daudi cells were maintained in RPMI with 10%
heat-inactivated FCS. Antibodies were: rabbit antisera to
BLIMP1 (28), rabbit polyclonal antibodies to IRF-1 and
IRF-2 (Santa Cruz) non-immune rabbit IgG (Upstate
Biotechnology) and mouse monoclonal antibody to
b-ACTIN (clone AC15, Sigma).
For siRNA-knockdown, U266 cells were electroporated
with 400 pmol of siRNA (200 pmol each BLIMP1 oligo or
400 pmol Control oligo) using a BioRad Gene Pulser at
250V and 960 mF. Twenty-four hours post-transfection,
cells were processed for protein and mRNA or chromatin
evaluation. The oligos used were:
BLIMP1 siRNA #1 sense sequence 50-GGAAAGGACC
UCUACCGUU-30
BLIMP1 siRNA #2 sense sequence 50-GAUCUGACCC
GAAUCAAUG-30
Control siRNA sense sequence 50-CUACCUCUAGAAC
GGACGU-30
ChIP ampliﬁcation, target validation and mRNA
quantiﬁcation
Chromatin immunoprecipitation and T7 ampliﬁcation
were performed as described except RNA was puriﬁed
with TRIzol (Invitrogen) (28,31).
Quantitative real-time PCR was performed using SYBR
Green MasterMix on an ABI Prism 7500 system (Applied
Biosystems). The precipitated material was quantiﬁed
against a standard curve of input DNA and normalized
relative to control immunoprecipitates. RNA was puriﬁed
with TRIzol (Invitrogen) and subject to DNase I treat-
ment (DNAFree, Ambion). cDNA was generated using
oligo-dT primer and Superscript II (Invitrogen). Relative
mRNA expression was normalized to GAPDH.
Arrays and hybridization
NimbleGen RefSeq hg18 promoter tiling arrays (design
ID 4226, design name 2006-07-18_HG18_RefSeq_
promoter) were used. Labelling, hybridization and data
acquisition was performed by NimbleGen according to
standard procedures with the modiﬁcation that ampliﬁed
material from control and speciﬁc ChIPs were directly
co-hybridized. Three independent control and speciﬁc
samples from the U266 cell line were evaluated. A
dye-swap replicate was included for one pair of samples.
For the control Daudi cell line, two independent control
and speciﬁc samples were hybridized.
Peak detection and ﬁltering
Peak detection was performed with the MA2C algorithm,
using a sliding window of 500 bp and a P-value cut-oﬀ of
0.001 (32). Data from the negative control Daudi cell line
provided experimental assessment of false positive detec-
tion rates. For further details, see Supplementary
Methods.
De novo motif analysis and matrix scoring
De novo motif detection was performed using Weeder
version 1.3 and Oligo-analysis (33,34). Sequence logos
were drawn using enoLOGOS (35). The STAMP web-
based tool for comparison of position weight matrices
(PWM) was used with default parameters (36).
Matches to PWMs were scored using RSAT
matrix-scan program (37). Distributions of all matches
at a range of predicted P-value thresholds were evaluated
in the MA2C deﬁned peak regions and in 106 randomly
selected sets of promoter regions of matched number,
length and position. Enrichment and statistical signiﬁ-
cance was determined by comparison of observed fre-
quency in peak regions and expected frequency derived
from 106 randomizations. For further details, see
Supplementary Methods.
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Promoter CpG content and conservation
Please see Supplementary Methods section for details of
analyses of promoter CpG content, and evolutionary
conservation.
Expression analysis
Gene expression was analyzed using Nimblegen arrays
(HG18_60mer_expr, hg18, NCBI Build 36); four
BLIMP1 knockdown and four control siRNA samples
were analyzed twice, giving a total of 16 data sets.
Labelling, hybridization and data acquisition was per-
formed by NimbleGen according to standard procedures.
Following analysis of raw data and comparison of correl-
ation, three BLIMP1 knockdown and three control arrays
were removed from analysis due to abnormal signal dis-
tributions. Remaining arrays were normalized with robust
multichip average (RMA) (38). A linear model was ﬁtted
using the R Limma package and signiﬁcance of diﬀerential
expression was gauged using Limma empirical Bayes stat-
istics module with probabilities adjusted for multiple
testing (Benjamini & Hochberg) (39). The enrichment of
groups of BLIMP1 target genes deﬁned by motif type was
assessed using a hypergeometric test of all genes showing
increases or decreases in expression above/below a range
of fold-change cut-oﬀs following BLIMP1 knockdown.
Luciferase assays
BLIMP1, IRF1 and control pIRES2-EGFP (Clontech)
modiﬁed by Myc-tag were as previously described
(28,40). pGL4-based luciferase reporter constructs for
promoters of AIM2 (hg17_chr1-:155859556-155860496),
BTN3A3 (hg17_chr6+:26,547,952-26,548,891) and SP110
(hg17_chr2-:230909991–230910891) were purchased from
SwitchGear Genomics. For mutated promoters, equiva-
lent insert sequences were synthesized (MrGene) with
overlapping BLIMP1/IRF sites identiﬁed in
Supplementary Table S1 mutated by the insertion of
XhoI restriction sites: AIM2 (TACTTTCGCTT to TAC
TCGAGAAT and CACTTTCTGTTTC to CACCTCGA
GAATC), BTN3A3 (CTTTCACTTTTC to CTCTCGAG
AATC), SP110 (ACTTTCACTTTTC to ACCTCGAGA
ATTC).
For luciferase assays, three replicate transfections were
performed for each condition. The indicated quantities of
expression vectors were co-transfected with reporter
luciferase vector and pRL-CMV control. For each condi-
tion, the total amount of vector transfected was
normalized by inclusion of control pIRES2-EGFP
plasmid. Experiments were done using the Promega
luciferase assay system and analyzed on a Berthold
Lumat LB Luminometer. Each experiment was performed
in duplicate with similar results. The data are from a rep-
resentative experiment displayed as fold increase in
relative light units relative to unstimulated cells
co-transfected with the empty vector.
Electrophoretic mobility shift assay
Nuclear extracts were prepared as previously described
from COS cells transfected with expression vectors for
BLIMP1 or IRF1 (28,40). For electrophoretic mobility
shift assay (EMSA), the double-stranded probes used con-
tained the following sequences, only one strand is shown:
AIM2 (50-ATGAGACCCAAGCGAAAGTATAGACAT
TTTA-30)
BTN3A3 (50-TGAAATGAAAAGTGAAAGTACATTG
AATTGT-30)
SP110 (50-AGAAAAGAAAAGTGAAAGTTTTCGGA
GTTTG-30)
IVNS1ABP (50-CGCACAGGGCGGCGAAAGTGAGG
GTGCGGGG-30)
RTN4IP1 (50-AAGTGGAGGGGGTGAAAGTGAGG
GAGGAGAA-30)
TLN1 (50-CCTCCAACGCAGCGAAAGTGACGCACC
CCAC-30)
For methylated oligonucleotides, the following se-
quences were used with symmetric methylation of both
strands, only the upper strand is shown:
AIM2 F (50-ATGAGACCCAAGC(Me)GAAAGTATA
GACATTTTA-30)
TLN1 F (50-CCTCCAAC(Me)GCAGC(Me)GAAAGTG
ACGCACCCCAC-30)
DNA probes [32P]-labelled with T4 polynucleotide
kinase were incubated with nuclear extract in the
presence of poly [dI:dC] (Amersham) for 30min at room
temperature. Supershift was performed by the addition of
antisera to the extract prior to mixing with radioactive
probe and competition assays included the addition of
unlabelled probe to the reaction mixture.
RESULTS
Deﬁning BLIMP1 occupied promoters
To establish an extended unbiased set of BLIMP1 targets,
we employed NimbleGen RefSeq promoter tiling arrays,
to examine ChIP samples generated from myeloma cell
line U266. The arrays include predicted promoters for
19 178 human RefSeq genes from on average 2.2 kb
upstream to 0.5 kb downstream of the transcriptional
start site (TSS), at density of 1 tile/100 bp. ChIP samples
were subject to T7 linear ampliﬁcation and equivalent en-
richment of known targets was demonstrated in ampliﬁed
material prior to further analysis (Supplementary Figure
S1) (31). Representative primary data for promoters of
STAT6, GLI3 and SP110 are shown (Figure 1A–C).
To test the overall false positive detection rate for
analysis, we performed BLIMP1 ChIP-chip from a
non-expressing cell line, Daudi. Peak detection was per-
formed using model-based analysis of two-colour arrays
(MA2C) and at a P=0.001 cut-oﬀ only a single peak
across all tiled promoter regions was identiﬁed in dupli-
cate samples from the Daudi cell line (32). At this cut-oﬀ,
286 promoter regions were identiﬁed as BLIMP1 occupied
across the four U266 data sets (Supplementary Table S1),
and did not include the single Daudi peak. This is similar
to the number of high-conﬁdence targets identiﬁed for the
transcription factor XBP-1 in plasma cells (41). Relaxing
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MA2C analysis stringency to identify additional occupied
promoters, resulted in a disproportionate increase in false
positive peaks in the Daudi data set (data not shown). A
low false positive detection rate was prioritized, and only
the results of stringent settings were used for further study.
Four genes (ELMOD3, RGS3, CCL4L1 and
HIST2H3C) were associated with two distinct regions of
promoter occupancy. Forty peak regions were in
bi-directional promoters, including the two peaks
associated with ELMOD3. Thus, a total of 322 unique
genes were linked with the 286 occupied promoter
regions (Supplementary Table S1). Overall, the BLIMP1
peaks demonstrated a strong clustering with 60% of peaks
present within 0.5 kb of the predicted TSS (data not
shown), consistent with preferential BLIMP1 binding in
the vicinity of predicted basal promoter elements.
Amongst the 286 high-conﬁdence peaks identiﬁed in the
U266 data were the known BLIMP1 target sites of
CIITA-pIII, MYC, PSMB8, PSMB10 and TAPBP. To
validate new targets, we chose a set of 27 peak regions
across a range of MA2C scores reﬂecting the robustness
of ChIP-chip signal (MA2C peak score for all targets:
range 3.8 to 0.76 mean peak score 1.22; MA2C peak
score for tested targets: 3.8 to 0.77, mean peak score
1.65) to test for BLIMP1 occupancy by conventional
qPCR analysis. The enrichment observed for the known
target PSMB8 (3.2±0.6) was set as a threshold for a
conﬁrmed interaction, equivalent to the weakest qPCR
enrichment observed at previously deﬁned targets (29).
Amongst the test set, 25/27 (92.6%) sequences were
enriched greater than or equal to this 3-fold threshold
(Figure 2A). To further assess the validity of the
ChIP-chip data, a predicted peak region was analysed in
detail by qPCR. STAT6 was chosen, since this gene has
previously been reported as repressed on BLIMP1
over-expression (3). Comparison of results between
ChIP-chip and qPCR analyses of this promoter
demonstrated a high degree of similarity in proﬁle.
Moreover, the pattern of binding was also conﬁrmed in
an alternate myeloma cell line, H929 (Figure 2B).
De novo motif detection conﬁrms BLIMP1
binding speciﬁcity
Two de novo motif discovery programs, Weeder and
Oligo-analysis, were employed to determine whether a
common BLIMP1 binding motif could be identiﬁed
amongst our peak regions, without prior knowledge of
motif composition. These programs rely on diﬀerent algo-
rithms and have performed well in head-to-head compari-
son with alternate programs (33,34,42,43). As a control,
ﬁve random sets of promoter sequences, matched to the
BLIMP1 peak regions for length and distribution relative
to TSS, were analysed. Amongst the 286 peak regions, the
Weeder program identiﬁed 14 distinct motifs of between 6
and 12 bp in length (Figure 3A and Supplementary Table
S2). By visual inspection, 13/14 of these matrices appeared
related, representing variations on a common theme. This
relationship was conﬁrmed by analysis with the STAMP
web-tool, which compares similarities between position
weight matrices (PWMs) and PWM databases
(Supplementary Figure S2A) (36). The results obtained
with the Weeder program were further conﬁrmed by inde-
pendent analysis of the peak regions with the Oligo-
analysis program, which identiﬁed an extended match to
the BLIMP1 consensus ‘AAGTGAAAGTGAA’, as the
most signiﬁcantly over-represented motif across the peak
regions (data not shown) (34).
Analysis against TRANSFAC v11.3 demonstrated that
the most signiﬁcant single match amongst the 13 related
matrices was to the TRANSFAC BLIMP1 motif
(M001066) (Supplementary Figure S2B). However, even
greater signiﬁcance was observed when aligning against
the high-aﬃnity in vitro weight matrix for BLIMP1
Figure 1. ChIP-chip identiﬁes BLIMP1 promoter occupancy.
Representative primary ChIP-chip data from genomic regions including
the promoters for STAT6 (A), GLI3 (B) and SP110 (C). Each panel
shows the average of U266 (black bars) and Daudi (grey bars) data
sets. The y-axis shows the log2 ratio of signal derived from hybridiza-
tion of speciﬁc BLIMP1 against control rabbit Ig ChIP samples. The
x-axis shows the genomic coordinates of micro-array tiles. The position
of the TSS for each gene is displayed.
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deﬁned by Kuo and Calame, which was not contained in
the version of TRANSFAC tested. Nine of 13 matrices
aligned more signiﬁcantly with this matrix than with any
matrix in the TRANSFAC database. Notably, other than
the alignment with BLIMP1 matrices, the most signiﬁcant
matches were observed to PWMs of the IRF family.
Amongst the ﬁve random promoter sets no matches to
BLIMP1 or IRF matrices of similar signiﬁcance were
observed (data not shown).
Motifs are highly enriched across a wide range
of thresholds
In order to distinguish between the individual Weeder
weight matrices (WWMs), we ﬁrst asked how signiﬁcant
the motif enrichment was in occupied promoter regions
for each WWM. To answer this question, we used a
boot-strapping approach to compare the observed occur-
rence of motif matches in our peak regions to the expected
occurrence of motif matches across all RefSeq promoters.
Using the RSAT matrix-scan program the RefSeq pro-
moters were scanned with each WWM, and the high
aﬃnity in vitro weight matrix for BLIMP1 (26,44). For
each matrix, the expected distribution of motif matches
was then determined by boot-strapping with random sets
of promoter regions, matching the set of BLIMP1
occupied regions for number, length and position
relative to TSS. This was performed across a full range
of quality thresholds with 106 random sets, generating
accurate distributions of motif matches. Comparison
with the observed distribution in the BLIMP1 bound
peak regions established the degree of enrichment and
the statistical signiﬁcance for each WWM
(Supplementary Figure S3A and data not shown).
Indeed, the family of related WWMs was enriched in the
bound promoter regions with very high signiﬁcance
(Table 1). This provides independent proof that the
WWMs represent a high-quality matrix set with a very
signiﬁcant association between the presence of these
motifs and BLIMP1 binding. However, the results also
demonstrate that relative enrichment does not provide a
clear single choice of optimal matrix.
Combinations of motifs capture distinct aspects of
binding speciﬁcity
Given the similarity and overall enrichment of the set of
WWMs, we next asked whether individual matrices were
redundant. We noted that the WWMs could be divided
into subclasses (Figure 3A). Ten of 13 related motifs con-
tained a common GAAAGT core, which is an extension
of the GAAAG core selected by BLIMP1 in vitro (26).
With increasing motif length, this core was ﬂanked by
50 or 30 extensions. Amongst longer motifs two distinct
sub-divisions were evident. First, matrices were
characterized either by a strict 50 GTG element, or a
more degenerate 50 GNG element. Secondly, WWMs of
either type were asymmetric with either a dominant 50 or 30
extension. Notably, the two most enriched matrices
identiﬁed in the boot-strapping analysis derived from
either extreme of 50 and 30 motif extension (Figure 3A
and Table 1).
To conﬁrm the validity of this in silico prediction, we
examined the ability of BLIMP1 to bind to oligonucleo-
tides representing variants of the 50 and 30 motif extension
types. The corresponding motifs for AIM2, SP110 and
BTN3A3 (50 motif extension type) as well as TLN1,
RTN4IP1 and IVNS1ABP (30 extension type) were
tested in EMSA with BLIMP1 containing nuclear
extracts. In each case, a single complex with BLIMP1
was detected whose speciﬁcity was demonstrated by
antibody supershift and competition with unlabelled
probe (Figure 3B). These data conﬁrm that motifs of
both the 50 and 30 extension type are directly bound by
BLIMP1.
The most enriched matrix variants thus appear to
capture distinct aspects of BLIMP1 binding speciﬁcity.
To directly test the degree of overlap between the
WWMs, we compared the four matrices corresponding
to GTG- or GNG-based motifs with longest 50 or 30 ex-
tensions. Each of these four closely related matrices
identiﬁed diﬀerent sets of signiﬁcant sites amongst
occupied promoters across a range of thresholds. Even
between highly similar matrix pairs, there were consider-
able diﬀerences in binding site prediction. For example,
when considering either the top 5 or 15% of matches each
Figure 2. Validation of BLIMP1 occupied promoters. (A) Real-time
PCR quantiﬁcation of BLIMP1 promoter occupancy in triplicate
ChIP samples from U266 cells. Data are displayed as mean fold
enrichment±SD relative to control rabbit IgG. Twenty-seven new
peak regions as well as three known targets (PSMB8, PSMB10 and
TAPBP) are shown. The known target PSMB8, was used as threshold
(3.2±0.6) to conﬁrm interaction. (B) Quantiﬁcation of BLIMP1
binding across the identiﬁed peak region spanning the STAT6
promoter by real-time PCR. The x-axis shows co-ordinates on human
chromosome 12 (hg18). Grey lines represent the mean fold
enrichment±SD from three ChIP samples relative to control IgG
from U266 myeloma cells. Black lines show the equivalent data from
an additional myeloma cell line H929 myeloma. The background en-
richment at unoccupied promoter regions is below 2-fold.
5340 Nucleic Acids Research, 2010, Vol. 38, No. 16
of the WWM quartet (WWM-Q) contributed a distinct as
well as overlapping set of binding site predictions
(Figure 4A). Thus, none of these matrices could be
regarded as redundant.
We next asked whether the in vitro derived BLIMP1
matrix contributes substantial information to the
predictions of this quartet of matrices. The in vitro
matrix is robustly enriched in bound promoter regions,
to the same degree as the most enriched WWMs
(Table 1), and at very stringent motif thresholds added
information to binding site predictions of WWM-Q.
However, with increasing degeneracy, the contribution
of the in vitro matrix declined, and the top 15% of motif
predictions of the WWM-Q captured all of the motif pre-
dictions of the in vitromatrix at this threshold (Figure 4B).
In contrast, in order to capture the set of targets identiﬁed
by the top 15% of WWM-Q matches with the in vitro
matrix alone, 92% of all potential sites across the
genome would have to be accepted as matches (data not
shown). We conclude that a single matrix is not suﬃcient
to encompass the binding speciﬁcity of BLIMP1, that
de novo motif prediction from in vivo binding data
captures complexity that is not evident from in vitro oligo-
nucleotide selection, and that a quartet of matrices
provides a more complete representation of BLIMP1 spe-
ciﬁcity. We will consider two consequences of the recog-
nition of these motif variants.
Motif type, CpGs and methylation sensitive DNA binding
The GNG element in WWM-9 and WWM-11 accommo-
dates a group of motifs containing a GCG triplet
(Figure 3A and Supplementary Table S1), which may be
Figure 3. De novo motif detection of the in vivo BLIMP1 binding consensus. (A) Sequence logos for 7 out of 14 matrices derived by the Weeder
program from occupied promoter regions are shown. These represent two themes around a common core element: a more ‘GTG’ or less ‘GNG’
restrictive 50 triplet, and either additional 50 or 30 extensions. (B) EMSA was performed with nuclear extracts from BLIMP1 transfected COS cells
and oligonucleotides corresponding to a range of 50 (AIM2, BTN3A3 and SP110) or 30 extension sites (IVNS1ABP, RTN4IP1, TLN1). BLIMP1
complexes (arrow) were identiﬁed by antibody supershift (Ab), and speciﬁcity of interaction was conﬁrmed by competition with 100- or 10-fold excess
of unlabelled probe (wedge).
Table 1. Enrichment of matrices in occupied promoter regions
Matrix Median enrichment Median P-value Median Z-score
In vitro 5.63 <10-6 16.96
W10-BO 4.59 <10-6 15.94
W13-BO 4.89 <10-6 15.79
W9-BO 4.15 <10-6 13.57
W5-BO 3.92 <10-6 13.23
W7-BO 2.84 <10-6 11.87
W6-BO 3.09 <10-6 11.57
W4-BO 3.17 <10-6 11.00
W2-BO 1.79 <10-6 10.41
W12-BO 3.34 <10-6 10.33
W11-BO 2.84 <10-6 8.45
W8-BO 2.50 0.000026 7.64
W3-BO 1.58 <10-6 6.25
W1-BO 1.29 0.001454 3.17
Enrichment of matches to the family of related WWMs or the in vitro
matrix for BLIMP1 was determined by comparison to 106 randomly
selected matched promoter regions for four motif quality thresholds
(top 5, 10, 15 and 20%). Shown are the median enrichment, median
P-values and median Z-scores across all thresholds.
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preferentially associated with CpG rich islands.
Examining the overall distribution of CpG sequences in
bound promoter regions demonstrated that BLIMP1 oc-
cupancy is not generally associated with a bias in
CpG-content. Bound promoter regions follow a distribu-
tion broadly similar to the biphasic pattern of all RefSeq
promoters (Figure 5A and B; 45). However, there was a
signiﬁcant (P=0.019, Wilcoxon signed-rank test) increase
in the CpG content of bound promoter regions associated
with a high quality motif match of GCG type, relative to
those without (Figure 5A and C). Since CpGs tend to be
clustered within promoters, this enrichment most likely
reﬂects binding within CpG islands. Indeed, for these pro-
moters, the CpG content of the BLIMP1 bound regions
exceeded the CpG content of the corresponding total
promoter region (Figure 5D). Thus, while there is no
overall skewing in the CpG content of BLIMP1 bound
promoter regions, WWM-9 and WWM-11 identify a
subset of BLIMP1 motifs preferentially associated with
regions of increased CpG content.
Methylation sensitive recognition of CpG containing
binding sites is a feature of the zinc-ﬁnger transcription
factor CTCF, and plays an important role in regulating
CTCF occupancy (46). We therefore asked whether
BLIMP1 binding to CpG containing motifs shows a
similar regulation, using GCG type motifs in the context
of either 50 (AIM2) or 30 (TLN1) extensions. Indeed,
methylation of a single CpG (AIM2) or two CpGs
(TLN1) eﬃciently abolished the binding of BLIMP1
(Figure 5E). In addition, even when added at 100-fold
excess unlabelled methylated oligonucleotides failed to
compete with non-methylated oligonucleotides for
BLIMP1 binding. In contrast, methylated oligonucleo-
tides retained the ability to compete eﬃciently for
binding with factors distinct from BLIMP1 (Figure 5E).
These experiments conﬁrm the idea that BLIMP1 binding
to CpG-containing motifs could potentially be regulated
by DNA-methylation in vivo.
Deﬁning the extent of overlap between BLIMP1 and IRF
motifs at occupied promoters
BLIMP1 and IRFs share a minimal GAAA core at virtu-
ally all sites, but show distinct preferences for surrounding
sequence contexts (26,27,47). This potentially allows for
the existence of three groups of target sites, one shared set
and one set selective for either IRFs or BLIMP1. For
IRFs, a strongly preferred context is given by the
extended AANNGAAA core sequence. This is supported
by in vivo and in vitro target site selection and crystal
structure (26,27,44). However, overlap with this
AANNGAAA IRF core is only favoured in BLIMP1
matrices with 50 extension, since these also have heavy
weighting for a 50 AA doublet. In contrast, the WWMs
with 30 extension (WWM-11 and -13) place no constraint
on the equivalent positions and may identify sites unique
to BLIMP1. Thus, our de novo motif analysis supports the
existence of distinct sets of BLIMP1 binding sites, which
either do or do not overlap with an extended IRF consen-
sus. Amongst the high-quality (top 15% WWM-Q)
BLIMP1 sites identiﬁed in occupied promoters 47%
contain an AANNGAAA and 53% do not
(Supplementary Table S3). In contrast, only 33% of all
potential BLIMP1 sites across tiled RefSeq promoters,
deﬁned at the same WWM-Q threshold, are of the
AANNGAAA type. Overlapping BLIMP1/IRF sites are
thus signiﬁcantly enriched amongst occupied promoter
regions (Fischer’s exact test P=1.59e-09). However,
these data also conﬁrm that a substantial subset of
BLIMP1 occupied promoters is characterized by motifs
that do not overlap with the extended IRF consensus.
The intersection between BLIMP1 and IRF DNA
binding speciﬁcities is likely to be evolutionarily ancient,
since both BLIMP1 and IRF orthologues exist in sea
urchin, the zinc-ﬁnger domains of BLIMP1 are highly
conserved, and BLIMP1 proteins encoded by evolutionar-
ily distant orthologues display the same motif restricted
ability to inhibit an IFNg responsive promoter
(17,29,48,49). Binding sites selected for regulation by
both BLIMP1 and IRFs should therefore also show a
higher degree of evolutionary conservation. To address
this idea, a set of non-redundant BLIMP1 binding site
predictions was generated for the bound promoter
regions. Ranked lists were compiled according to conser-
vation scores calculated from the sum of each position of
the motif match for either primate or vertebrate conserva-
tion. Fischer’s exact test was then used to compare the
percentage of BLIMP1 sites with or without an IRF
overlap in equal fractions from the top (most conserved)
or bottom (least conserved) of this list. Across a broad
range, overlapping sites showed a signiﬁcant association
Figure 4. Related matrices provide non-redundant information. (A)
Venn diagrams display the intersection between the sets of genes
linked to promoters with signiﬁcant matches to the quartet of
matrices WWM-9, WWM-10, WWM-11 and WWM-13, which repre-
sent the extremes of motif variants. Results are shown at two thresh-
olds: top 5% of matrix matches (left) and top 15% of matrix matches
(right). (B) Displayed are the overlap between the in vitro matrix for
BLIMP1 and the combined results of WWM-quartet (WWM-Q).
Results are displayed for two thresholds: top 5% of matrix matches
(left) and top 15% of matrix matches (right).
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Figure 5. Motif type, CpGs and methylation sensitive DNA binding. (A) Graph of CpG content of all tiled promoter regions, and (B) graph of the
distribution of CpG content in all BLIMP1 occupied promoters. Median CpG ratio of occupied promoter regions containing a top 15% WWM-Q
match with GCG triplet (solid line) or a top 15% WWM-Q match without GCG triplet (dashed line). y-Axes, number of promoter regions; x-axes,
ratio of observed to expected CpG content [number of CpG/(Number of CNumber of G)sequence length], bin size=0.02. (C) Box-plot of CpG
content in bound peak regions containing a top 15% BLIMP1 motif match with GCG triplet (left) and a top 15% BLIMP1 motif match without
GCG triplet (right), and (D) box-plot comparing tiled promoter (PR) regions to bound peak (BP) regions for occupied promoters with a top 15%
BLIMP1 motif match containing a GCG triplet. y-Axes, ratio of observed to expected CpG content described above. (E) EMSA was performed with
nuclear extracts from BLIMP1 transfected COS cells and oligonucleotide probes corresponding to AIM2 (left panel) or TLN1 (right panel) sites,
respectively. Within each panel, the left six lanes show EMSAs with a labelled unmethylated probe, whereas the right two lanes show EMSAs done
with probes containing symmetrically methylated CpGs. The expected BLIMP1 complexes (arrows) were observed with the labelled unmethylated
probe and conﬁrmed by antibody supershift (competitor: Ab) but did not form with methylated probes. To conﬁrm loss of BLIMP1 binding to
methylated probes, cold competition was performed with a 100- or 10-fold excess of unmethylated unlabelled competitor (competitor: C) or
methylated unlabelled competitor (competitor: MeC). Circles indicate other protein–DNA complexes distinct form BLIMP1 whose binding was
not abolished by DNA methylation.
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with better conservation scores (Table 2). To establish
how motif quality related to conservation and motif type
in occupied promoters, we examined the P-value distribu-
tions of the two BLIMP1 motif types in the top and
bottom fractions of the ranked list. Similar distributions
were observed for both primate and vertebrate conserva-
tion and demonstrated that relative to other sites,
overlapping BLIMP1/IRF sites with higher conservation
scores are skewed away from high and toward low
P-values (Supplementary Figure S4). Thus, conserved
BLIMP1/IRF sites have a tendency to be better quality
motif matches than non-conserved sites. Such skewing was
not evident for sites lacking IRF overlap. These ﬁndings
support the contention that functional antagonism is
subject to evolutionarily conservation.
We have previously shown that mutation of position 3
and 9 of the in vitro derived BLIMP1 consensus from G to
C in the context of overlapping BLIMP1/IRF-E sites ab-
rogates the ability of BLIMP1 to bind to DNA, but does
not alter binding of IRF1/IRF2 or regulation by IFNg
(28,29). Amongst the top 15% of IRF1, IRF2 or
ISGF-3 (ISRE) sites in human RefSeq promoters
(deﬁned using TRANSFAC M00062, M00063 and
M00258), respectively, 21%, 14% and 22% of matches
contain a C at both critical positions that prevent
BLIMP1-dependent regulation. This predicts that
BLIMP1 is excluded from a signiﬁcant fraction of IRF
sites. If this holds true across the genome, sequences
related to the consensus AACTGAAACT should not be
enriched amongst BLIMP1 occupied promoters. We
therefore repeated the boot-strapping analysis of
promoter regions using versions of the WWM-Q or the
in vitro BLIMP1 matrix in which the corresponding
position weighting was switched from G to C
(Supplementary Table S2). In contrast to the original
matrices, these ‘mutated’ matrices were minimally
enriched amongst bound promoter regions, indicating
that BLIMP1 distinguishes between these closely related
sites (Figure 6 and Supplementary Figure S3A and B).
Thus, the results we previously observed with a limited
set of promoters can be extrapolated across the genome
(28,29). This conﬁrms that a subset of IRF sites remains
unoccupied by BLIMP1, and that selectivity is exerted on
both sides of the antagonistic BLIMP1/IRF module at the
level of cis-regulatory element occupancy in vivo.
Overlapping BLIMP1/IRF motifs identify sites of
dynamic repression
The antagonistic regulation model predicts that in cells
expressing competing BLIMP1 and IRFs, genes whose
promoters contain overlapping BLIMP1/IRF motifs
should be enriched amongst genes that are increased in
expression after BLIMP1 knockdown. U266 cells express
IRFs, including IRF1, which we have shown to activate
gene expression in direct competition with
BLIMP1-dependent repression (28,29). To verify that
IRFs can compete with BLIMP1 for occupancy at target
promoters in U266 cells, we assessed the binding of IRF1
to a selection of promoters linked to predicted overlapping
BLIMP1/IRF sites. As expected IRF1 binding was
detected by ChIP across the range of promoters tested
(Supplementary Figure S5), demonstrating that these rep-
resent potential in vivo IRF targets and that this cell line
therefore provides a model system in which to test the
prediction.
We next examined gene expression changes after
BLIMP1 knockdown in U266 cells (Figure 7A). First, 15
targets were tested by qPCR of which 12 showed an
average increase of expression of 1.5-fold, with six
genes showing 1.9-fold increases in expression
(Figure 7B). We then examined global changes in gene
expression by micro-array. BLIMP1 target genes
showing the most signiﬁcant changes included BCAT1,
LMO2, BTN3A3, CIITA, CSF1 and SP110
(Supplementary Table S4). To assess whether the
presence of a BLIMP1/IRF motif was associated with
an increase in gene expression, we subdivided BLIMP1
occupied promoters into three groups and asked whether
motif type was predictive of a change in gene expression.
The groups of genes considered were those linked with: (i)
promoters containing a top 15% match to the WWM-Q
with IRF overlap (n=86), (ii) promoters containing a top
15% match to the WWM-Q without IRF overlap
(n=76), (iii) all other genes linked to occupied promoters
not included in groups (i) or (ii) (n=160). Gene expres-
sion changes on BLIMP1 knockdown were separated into
increased or decreased expression relative to control
siRNA-treated samples, and then according to
fold-change greater than or equal to cut-oﬀs starting
from 1.4-fold. A hypergeometric test was used to assess
Table 2. Conservation analysis for BLIMP1 motif matches in occupied promoters
Percentage of
ranked list
Primate PhyloP conservation Vertebrate PhyloP conservation
Top
percentage
with IRF
Bottom
percentage
with IRF
FETpVal Top
percentage
with IRF
Bottom
percentage
with IRF
FETpVal
10 17.03 7.42 1.01E-04 15.11 9.07 1.66E-02
20 15.11 8.10 3.85E-05 15.52 9.20 3.20E-04
30 13.92 8.61 1.08E-04 14.38 8.33 1.05E-05
40 13.32 9.00 2.54E-04 12.98 9.00 7.13E-04
The table shows results for PhyloP conservation and is divided by primate or vertebrate score. Rows are divided by incremental conservation
fractions, while columns show the percentage of BLIMP1 motif matches with IRF overlap in the corresponding top (most) or bottom (least)
conserved fractions. The signiﬁcance of enrichment was calculated using Fischer’s exact test.
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the probability of ﬁnding the observed distribution of
target genes associated with each of the BLIMP1 motif
types amongst the genes in each expression change
category (Figure 7C). Strikingly, target genes linked to
group (i) were signiﬁcantly associated with a positive
change in gene expression on BLIMP1 knockdown
across all fold-change cut-oﬀs tested. In contrast, genes
in groups (ii) or (iii) showed no signiﬁcant association
with a positive change in gene expression. When
examining all genes with reduced expression following
BLIMP1 knockdown no consistently signiﬁcant associ-
ation with any of the groups was seen (data not shown).
To test whether the observed change in gene expression
corresponded to the predicted shift in promoter occu-
pancy from BLIMP1 to IRF, ChIP was performed follow-
ing BLIMP1 knockdown. This demonstrated that loss of
BLIMP1 protein expression was consistently linked both
to a drop in promoter occupancy by BLIMP1 and to an
increase in promoter occupancy by IRFs (Figure 7D). We
next conﬁrmed by EMSA that the predicted overlapping
binding motifs present in dynamically regulated pro-
moters (AIM2, BTN3A3 and SP110) were indeed IRF
sites (Figure 8A). Consistent with the motif sequences,
IRF1 bound as a single complex to the AIM2 site (long
arrow). In contrast, two complexes of diﬀerent mobilities
were observed for the more extended BTN3A3 and SP110
sites (long and short arrows), with the slower mobility
complexes consistent with cooperative binding by two
IRF1 proteins (27,29). To demonstrate the functional sig-
niﬁcance of these sites for promoter regulation, luciferase
constructs in which the overlapping BLIMP1/IRF sites
were retained or mutated were co-transfected with
BLIMP1 and/or IRF1 expression vectors (Figure 8B).
The wild-type promoters were induced by IRF1 and re-
pressed by BLIMP1. Promoter activation by IRF1 was
eﬃciently repressed by BLIMP1 at low doses (left
panels), but with higher amounts of IRF1 repression
was partially overcome (middle panels). The presence of
identiﬁed binding motifs was essential both for
BLIMP1-dependent promoter repression, and for
IRF-dependent promoter enhancement, since neither
factor mediated these eﬀects in promoters in which
binding sites were disrupted by mutagenesis (right panels).
Finally, we considered that the presence of an
overlapping BLIMP1/IRF motif alone, rather than the
presence of such a motif in an occupied promoter could
be the important factor in predicting response following
BLIMP1 knockdown. We therefore used the same criteria
(WWM-Q top15% with IRF overlap) to identify all genes
linked to promoters containing BLIMP1/IRF motifs, and
repeated the analysis of the global gene-expression data.
This group of all potential target genes showed minimal
association with a positive change in gene expression
(Supplementary Figure S6). Moreover, removing
BLIMP1 occupied promoters from this gene set
eliminated any residual association indicating that it is
unlikely that there is a substantial group of dynamic
target genes amongst this gene set that we have not
detected. We conclude that it is the combination of
BLIMP1 occupancy and motif type rather than motif
type per se that predicts a positive change in gene expres-
sion on BLIMP1 knockdown in this system. The associ-
ation between occupancy and promoter motif type with
response to BLIMP1 knockdown, the observed shift in
transcription factor occupancy after knockdown and the
requirement for individual binding sites in reporter assays,
therefore conﬁrm the central prediction of the antagonistic
regulation model and identify a dynamic set of BLIMP1
target elements linked to the presence of overlapping
BLIMP1/IRF sites.
DISCUSSION
In this study, we set out to address whether unbiased
analysis of BLIMP1 occupancy across promoters of the
human genome would support the functional relevance of
overlap between BLIMP1 and IRF binding sites, and the
existence of distinct target gene subsets. Our approach has
been to deﬁne an extended but stringent set of targets and
then use a rigorous analysis of motif representation. The
results contribute in a number of ways to our understand-
ing of the biology of BLIMP1.
Multiple non-redundant matrices describe
BLIMP1 speciﬁcity
We have used our in vivo target set to determine that the
previously deﬁned in vitro BLIMP1 binding motif
provides a robust overall representation of binding speci-
ﬁcity in vivo (26). However, our analysis of motif repre-
sentation also indicates that the in vitro-deﬁned BLIMP1
matrix does not fully capture binding speciﬁcity. De novo
motif detection identiﬁes a family of motifs, all of which
show substantial similarity to the in vitro consensus.
However, this family of motifs also identiﬁes signiﬁcant
heterogeneity in motif selection. Two aspects of this result
are the identiﬁcation of motifs with a preferential 30 rather
than 50 extension, and motifs allowing greater degeneracy
at key positions. The signiﬁcance of these ﬁndings is
veriﬁed since these motifs act as genuine BLIMP1
Figure 6. In silico ‘mutagenesis’ identiﬁes potential IRF motifs not
subject to antagonistic regulation. The graph displays the fold enrich-
ment (y-axis) of the WWM-Q (solid lines) and ‘mutated’ variants
(broken lines) across 20 motif thresholds (x-axis) compared to 106
matched random promoter regions. Values for original WWM-Qs are
as in Table 1: WWM-9 (blue lines), WWM-10 (red lines), WWM-11
(yellow lines) and WWM-13 (black lines).
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binding sequences in vitro, and promoters containing such
sites are occupied in vivo. Furthermore, it is of note that in
the original random nucleotide selection data for human
BLIMP1 (PRDI-BF1), three out of ﬁve clones had one or
more adenosines 30 of the central GTGAAAGTG (25).
The motif identiﬁed by the alternate Oligo-analysis algo-
rithm, also supports the signiﬁcance of the 30 extension.
However, Oligo-analysis compiles the motifs into an
extended symmetrical sequence. We directly tested
whether merging shorter matrices into longer symmetrical
motifs added to prediction eﬃciency, but there was no
appreciable beneﬁt over using pairs of independent
matrices (data not shown).
One question emerging from the prediction of a family
of similar motifs was whether these provided redundant
information. It was not surprising to ﬁnd that the matrices
with 50 or 30 extensions failed to overlap in many cases and
represented distinct binding preferences. However, the dif-
ferences observed between GTG- and GNG-containing
matrices (WWM-10 versus WWM-9 and WWM-13
versus WWM-11) demonstrated the degree to which rela-
tively subtle variations in matrix composition substantial-
ly impact on motif identiﬁcation in occupied promoters.
Thus, over a range of motif thresholds none of the
matrices tested could be viewed as redundant. Choosing
a single consensus or PWM to represent BLIMP1 binding
speciﬁcity would therefore ignore signiﬁcant information.
The primary explanation is likely to be the impact of
interdependencies between binding site positions since
these are not captured in PWMs, and can be a feature
of C2H2 Zn-ﬁnger transcription factors (50,51). A
number of groups have begun to address the utility of
using mixtures of PWM to represent factor binding, and
the importance of considering interdependencies for
speciﬁc transcription factors (52–54). Recently, distinct in-
stances in which in vitro binding data require multiple
PWMs to represent speciﬁcity have been elegantly
demonstrated for several murine transcription factors,
but BLIMP1 was not amongst the DNA-binding
domains tested (55). Our data demonstrate that multiple
PWMs are required to eﬃciently describe BLIMP1
binding speciﬁcity, and in this study we have taken a prac-
tical approach adopting a quartet of matrices to represent
variations in preferences. However, further studies with
more advanced representations will be important in
future.
Figure 7. Occupancy and motif type deﬁne a distinct subset of dynam-
ically regulated BLIMP1 targets. (A) siRNA knockdown of BLIMP1 in
U266 myeloma cells. Quadruplicate samples of U266 cells were trans-
fected with control siRNA or siRNA directed against BLIMP1. The
protein levels of BLIMP1 and b-ACTIN present in cell lysates were
determined 24 h post-transfection. (B) Alteration of BLIMP1 target
gene expression in siRNA-treated U266 cells. Changes in expression
of individual target genes were evaluated by quantitative RT-PCR.
Shown are representative target genes with expression normalized to
GAPDH and displayed as fold-change (y-axis) in expression relative to
control siRNA-treated samples. (C) Global gene expression changes in
siRNA-treated samples were evaluated on NimbleGen micro-arrays.
BLIMP1 target genes were divided into three groups according to
motif type: (i) those whose promoters contain a top 15% WWM-Q
match with IRF overlap (black ﬁll), (ii) those whose promoters
contain a top 15% WWM-Q match without IRF overlap (grey ﬁll)
(iii) all other occupied promoters (vertical stripes). The enrichment of
these target genes amongst all genes showing an increase in expression
above fold-change cut-oﬀs from 1.4- to 2-fold was evaluated using a
hypergeometric test. The observed enrichment for each group amongst
genes changing expression is shown in the upward bars, the signiﬁcance
of this enrichment is shown as the log10 of the P-value in downward
bars. The dotted line represents P 0.05. (D) Dynamically regulated
promoters show a shift in occupancy from BLIMP1 to IRFs following
BLIMP1 knockdown. U266 cells were transfected with control siRNA
or siRNA directed against BLIMP1. ChIP was performed with control
antibody and antibodies speciﬁc to BLIMP1 or a mixture of antibodies
recognizing IRF1 and IRF2. Enrichment of promoter fragments was
determined for control and BLIMP1 siRNA transfected cells. The per-
centage change (y-axis) in enrichment for each promoter
(BLIMP1-siRNA ChIP/Control siRNA ChIP) is displayed. Bars show
the range of values observed for duplicate ChIP samples (IRF: grey
bars, BLIMP1: black bars). Results are representative of three inde-
pendent experiments.
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Implications for DNA binding and methylation sensitivity
Methylation of the ﬁrst three guanosine residues of
the BLIMP1 consensus sequence within the positive
regulatory domain I (PRDI) of the IFN promoter abro-
gates binding (24). These three guanosines are heavily
weighted amongst the WWMs, and the importance of
two of these positions is underlined by the eﬀect
of mutating G to C that we have previously demonstrated
(28,29). The recognition of distinct matrix variants around
these key contact points has interesting implications
with regard to the nature of the BLIMP1 DNA interaction
and the contribution of the ﬁve BLIMP1 Zn ﬁngers to
binding speciﬁcity. The contribution of BLIMP1 Zn
ﬁngers to DNA binding was tested using LacZ fusion
proteins in the context of a concatamer of the IFN
promoter PRDI, representing sequential BLIMP1 sites
with 50 and 30 extensions (12). Zn ﬁngers 1 and 2 were
suﬃcient to confer speciﬁcity to this sequence, but
Figure 8. Overlapping BLIMP1/IRF binding sites bind IRF1 and mediate IRF1 and BLIMP1-dependent gene regulation. (A) EMSA was performed
with nuclear extracts from IRF1 transfected COS cells and oligonucleotides containing an overlapping BLIMP1/IRF site (AIM2, BTN3A3 and
SP110). IRF1 complexes were identiﬁed by antibody supershift (Ab), and speciﬁcity of interaction was conﬁrmed by competition with 100- or 10-fold
excess of unlabelled probe (wedge). IRF1 bound as a single molecule is indicated by a long arrow, whereas co-occupancy of the site by two molecules
of IRF1 is indicated by short arrows. (B) HeLa cells were co-transfected with vectors carrying luciferase reporter constructs driven by wild-type
promoters of the indicated genes or promoters where IRF/BLIMP1 overlap sites were mutated, together with empty vector (cont), two diﬀerent
amounts of IRF1 (5 ng or 20 ng), and/or BLIMP1 (5 ng) expression vectors. Luciferase activity was assayed 24 h post-transfection. Luciferase activity
(y-axis) is displayed normalized to renilla and relative to the control transfected sample. Data are derived from triplicate samples and are displayed as
the mean±SD.
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required additional appropriate N-terminal residues
in order to mediate binding. Zn ﬁngers 3–5 were not
necessary to mediate recognition of the PRDI concatamer.
However, all ﬁve Zn ﬁngers together appear to
show enhanced recognition in these assays and binding
aﬃnities of the various Zn-ﬁnger combinations were
not directly assessed (12). The orientation of BLIMP1
Zn-ﬁngers relative to the target site is not known,
but the existence of motif variants with either 50 or 30
extensions suggests that both additional N- and
C-terminal sequences may contribute to DNA recognition
depending on circumstance. This would imply that
C-terminal Zn ﬁngers contribute to recognition of a
subset of BLIMP1 target sites, most likely those with 30
extensions.
The recognition of GNN triplets is a common feature
amongst C2H2 Zn-ﬁnger domain proteins, and several
examples recognizing GTG or GCG triplets have been
identiﬁed (51). This is a common sequence element
recognized at either end of the extended BLIMP1 consen-
sus. The occurrence of a subset of sites with CpG residues
suggested that like CTCF, which is another Zn-ﬁnger
transcription factor with repressive activity, binding of
BLIMP1 to some of its targets could be regulated by
DNA methylation (46,56). Indeed, we show that the
ability of BLIMP1 to bind to its target sequences is
eliminated by CpG methylation. In the WWMs, a GCG
is better tolerated at the 50-end of the BLIMP1 binding
site. Thus, as in the case of CTCF, speciﬁc interactions
with one Zn ﬁnger may be the target of
methylation-dependent regulation (46). BLIMP1 can
initiate the process of epigenetic silencing which may even-
tually lead to DNA methylation (15). This suggests an
interesting model in which BLIMP1 is actively excluded
from a subset of its target sites, once silencing at the level
of DNA methylation is established.
Motif type deﬁnes a dynamic target set
The model of interaction between BLIMP1, IRFs and
IFNs originates from the initial identiﬁcation of
BLIMP1 as a repressor of the IFN promoter where
multiple IRFs act to control gene expression (24).
IRF1 and IRF2 directly compete with BLIMP1 for
regulation of IRF-Es and this is dependent on the
precise sequence of the IRF-E, since two point muta-
tions are suﬃcient to eliminate BLIMP1 binding and
regulation (28,29). Such antagonistic regulation provides
a molecular mechanism by which the cellular re-
sponses driven by BLIMP1 intersect with those
driven by the cytokine milieu. Furthermore, other
members of the IRF family play key roles in cellular
responses to a diverse range of inﬂammatory signals,
and these provide further potential for antagonistic inter-
action (57,58).
In this study, the unbiased analysis of promoter occu-
pancy conﬁrms the frequent overlap between BLIMP1
and IRF motifs within occupied promoters and demon-
strates that this overlap is of general functional signiﬁ-
cance. Overlapping BLIMP1/IRF binding sites in
occupied promoters are signiﬁcantly enriched amongst
conserved promoter elements, suggesting an evolutionary
constraint on preservation of dual regulation. Genes
whose promoters harbour occupied overlapping
BLIMP1/IRF motifs are much more likely to show in-
creases in expression following BLIMP1 knockdown in
a cell type co-expressing BLIMP1 and IRFs (28).
Moreover, it is the combination of occupancy and motif
type rather than motif type per se which governs this
response. In an experiment in which expression of a tran-
scriptional repressor is knocked down, high aﬃnity sites
are expected to be subject to the most robust repression,
and be amongst the least de-repressed of targets. Instead,
we observe the opposite result and the most labile genes
are associated with high-quality BLIMP1 sites (compare
responses of group (i) and group (iii) in Figure 7C). This is
not a feature of all genes associated with high-quality
BLIMP1 sites but is restricted to the subset that shows
overlap with an IRF consensus, and correlates with a
shift in promoter occupancy from BLIMP1 to IRF fol-
lowing BLIMP1 knockdown. This response, therefore,
conﬁrms a prediction of the antagonistic regulation
model, and identiﬁes a set of BLIMP1 targets subject to
dynamic repression. Genes included in this set are: tran-
scriptional regulators SP110, NFIX, CREB3, ATF3 and
GLI3, and immune response regulators AIM2, IFIT2,
PSMB10 and TAPBP.
Target genes and function
Finally, the target list itself provides important insights
into novel genes and functions regulated directly by
BLIMP1. These are likely to be of relevance beyond the
B-cell lineage. Brieﬂy, genes of particular note encode the
transcription factors: FOXP1, necessary for early B-cell
development and LMO2 a critical regulator of early
haematopoietic diﬀerentiation both of which are also im-
portant prognostic markers in lymphoma (59–62); ATF3
that is involved in cellular stress responses and integration
of signalling pathways (63); ATF6 and CREB3 that are
transmembrane proteins cleaved to form active transcrip-
tion factors during the unfolded protein response of the
endoplasmic reticulum, a stress response essential to
plasma cell diﬀerentiation (64); and the glucocorticoid
receptor and nuclear transcription factor NR3C1 (65).
Other genes of note encode components of signalling
pathways such as: AIM2 that has recently emerged as a
central regulator of the inﬂammasome in response to
intracellular double-stranded DNA (66–68); PTPN6
(SHP1) a key negative regulator of B-cell signalling (69);
and PIK3CA and DGKA that encode central components
of lipid signalling pathways (70,71). A common theme
shared between several targets is involvement in aspects
of cellular stress responses. Given the potential role of
IRFs either in the regulatory elements controlling these
genes or the response to which they contribute
(57,65,72), and the induction of BLIMP1 by diverse
forms of cellular stress (24,40,73), we suggest these
targets identify an intersection between two aspects of
BLIMP1 function: stress-responsive induction and IRF
antagonism.
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